148 filings
Page 3 of 8
6-K
xswnen8zs42aj98ipi
16 Mar 22
Current report (foreign)
8:30am
424B3
rkd5c
9 Mar 22
Prospectus supplement
9:26am
424B3
dp6c1 zmqsh6
9 Mar 22
Prospectus supplement
9:25am
6-K
tfb6uzgs 7ev
9 Mar 22
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M
9:23am
424B3
c4czk8 ugaksqj
28 Feb 22
Prospectus supplement
12:02pm
424B3
r6t5or90agdr
28 Feb 22
Prospectus supplement
12:01pm
6-K
b4jfyc1 f5tva
28 Feb 22
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA
12:00pm
6-K
hqlbb5p h3uyl
25 Feb 22
Current report (foreign)
4:05pm
424B3
nemftaxc
31 Jan 22
Prospectus supplement
7:35am
424B3
tjesvjb
31 Jan 22
Prospectus supplement
7:33am
6-K
dgo94 pa0899
31 Jan 22
Current report (foreign)
7:32am
424B3
adxqogad6 e5e
23 Nov 21
Prospectus supplement
8:06am
424B3
onefveey9zccjuhr921
23 Nov 21
Prospectus supplement
8:05am
6-K
ighbie
23 Nov 21
Amryt Provides Update on Regulatory Review Process for Oleogel-S1
8:04am
424B3
eev6f1g2rnvwbi7o
22 Nov 21
Prospectus supplement
7:39am
424B3
c7571xx47to
22 Nov 21
Prospectus supplement
7:38am
6-K
7fclimt
22 Nov 21
Amryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
7:37am
424B3
ptbw408r1
3 Nov 21
Prospectus supplement
7:33am
424B3
j7kxcv
3 Nov 21
Prospectus supplement
7:32am
6-K
bq4b5 t62r5
3 Nov 21
Amryt Reports Strong Q3 2021 Results
7:31am